



Celectricon launches new system for ion channel drug screening

Gothenburg, Sweden, 10 November 2004: Celectricon today announced the launch of the new Dynaflo™ Proficient System for increased throughput in ion channel drug screening, following a beta-testing of the new 48-channel chip and software by GlaxoSmithKline.

Developed for life scientists and drug discovery researchers, the Dynaflo™ Proficient (Pro) System is an add-on to conventional patch-clamp and provides a solution to the current need for increased throughput in ion channel drug screening such as dose-response analysis. Ion channels represent an important class of drug targets since about fifteen percent of the top 100 best-selling drugs on the market target these membrane spanning proteins directly or indirectly. The Dynaflo™ Pro System integrates an unparalleled product line for both ligand- and voltage-gated ion channel drug screening with superior throughput, regardless of whether fast or slow acting compounds are used. It is the only system on the market that offer less cost per data point since it gives uncompromised and pharmacologically relevant data at a higher throughput.

The Dynaflo™ Pro System consists of the Dynaflo™ Pro Platform and can be used together with the new Dynaflo™ 48 channel chip (DF-48) and the existing Dynaflo™ 16 channel chip (DF-16). The new control software, the Dynaflo™ Commander Pro 1.0 has capability to run both chips. DF-48 is optimized for ligand-gated ion channels and has been beta-tested by GSK. DF-48 makes it possible to receive multiple compound dose responses per chip and cell and allows for up to 12 full dose response curves per day. Time-consuming and costly campaigns are now completed in weeks instead of months. The software, Dynaflo™ Commander Pro 1.0 gives the flexibility to easily pre-program experiments including scan protocols and exposure time which increases the scanning flexibility and gives full track record of performed experiments. The Dynaflo™ Pro System also integrates the previously launched DF-16 chip which has already been adopted by 8 of the world's top 10 pharmaceutical companies. DF-16 is optimized for voltage-gated ion channels where users easily can extract full dose responses from single cells and receive up to 5 full dose response curves per day.

"The development of the new platform and the 48-channel chip was guided by top-reference customer to meet the demands of total experimental flexibility. This new system opens up for completely new types of experiments," stated Cecilia Farre, Ph.D., Dynaflo™ Project Manager at Celectricon. "With Dynaflo™ Pro System, researchers' increases the throughput drastically thereby reducing the cost associated with patch-clamp based ligand- and voltage-gated ion channel drug screening. With Dynaflo Pro, users easily obtain full dose-response curves in significantly shorter time than with other systems."

About Celectricon

Celectricon AB (Gothenburg, Sweden) develops life science tools based on world leading science competences. The products target bottlenecks in the drug discovery process. The first generation of products, Dynaflo™, provides groundbreaking systems for ion channel drug discovery and offers dramatic productivity increase with major savings in both time and cost. The company was formed in 2000 based on an extensive and solid patent portfolio within different areas such as high-throughput electrophysiology, microfluidics, microfabrication, and electroporation. Celectricon is a privately held company and the main shareholders are InnovationsKapital, Investor Growth Capital and Karolinska Investment Fund.



Contact Details:

Axel Broms, Chairman

Phone: + 46 (0)705-27 92 10

axel.broms@bredband.net

Susanne Orwar, Communications Manager

Phone: +46 (0)31 760 35 15

susanne.orwar@cellectricon.se